PT  - JOURNAL ARTICLE
AU  - Zheng, Zhe
AU  - Warren, Joshua L.
AU  - Shapiro, Eugene D.
AU  - Pitzer, Virginia E.
AU  - Weinberger, Daniel M.
TI  - Estimated Incidence of Respiratory Hospitalizations Attributable to RSV Infections across Age and Socioeconomic Groups
AID  - 10.1101/2022.03.23.22272830
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.23.22272830
4099  - http://medrxiv.org/content/early/2022/03/24/2022.03.23.22272830.short
4100  - http://medrxiv.org/content/early/2022/03/24/2022.03.23.22272830.full
AB  - Background Surveillance for respiratory syncytial virus (RSV) likely captures just a fraction of the burden of disease. Understanding the burden of hospitalizations and disparities between populations can help to inform upcoming RSV vaccine programs and to improve surveillance.Methods We obtained monthly age-, ZIP code- and cause-specific hospitalizations in New York, New Jersey, and Washington from the US State Inpatient Databases (2005-2014). We estimated the incidence of respiratory hospitalizations attributable to RSV by age and by socioeconomic status using regression models. We compared the estimated incidence and the recorded incidence (based on ICD9-CM) of RSV hospitalizations to estimate the under-recorded rate in the different sub-populations.Results The estimated annual incidence of respiratory hospitalizations due to RSV was highest among infants <1 year of age with low socioeconomic status, (2700 per 100,000 people, 95% CrI [2600, 2900]) and were considerable in older adults that are ≥65 years of age across socioeconomic status, ranging from 130 to 970 per 100,000 people. The incidence of hospitalization recorded as being due to RSV represented a significant undercount, particularly in adults. Only <5% of the estimated RSV hospitalizations were captured for the older adults that are ≥65 years of age.Conclusions RSV causes a considerable burden of hospitalization in young children and in older adults in the U.S, with variation by socioeconomic group. Estimates of the incidence of hospitalizations due to RSV in older adults based on the recorded diagnoses likely represent an underestimate.What is already known on this topic?Previous study suggested that the incidence of hospitalization for bronchiolitis (often caused by RSV) in infants varies greatly between communities of different socioeconomic levels. However, it is unclear whether these differences are associated with the admission criteria or the risk of RSV infection.What this study adds?The estimated annual incidence of respiratory hospitalizations due to RSV in infants residing in low socioeconomic areas was about twice as high as the incidence in infants residing in high socioeconomic areas. In older adults, a small fraction of the hospitalizations estimated to be caused by RSV were recorded as such in the inpatient database.How this study might affect research, practice or policy?With several vaccines and extended half-life monoclonal antibodies against RSV under active development, these estimates can help anticipate the impact of RSV prevention strategies in populations of different demographic characteristics.Competing Interest StatementVEP has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements on respiratory syncytial virus. DMW has received consulting fees from Pfizer, Merck, GSK, Affinivax, and Matrivax for work unrelated to this manuscript and is Principal Investigator on research grants from Pfizer and Merck on work unrelated to this manuscript. All other authors report no relevant conflicts.Funding StatementResearch reported in manuscript was fully supported by the National Institute of Allergy and Infectious Diseases (MIDAS Program) of the National Institutes of Health under award number R01AI137093. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Yale University waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe demographic and geographic data that support the findings of this study are publicly available from the Geography program of the U.S. Census Bureau, the American Community Survey of the U.S. Census Bureau. The hospitalization data are not available publicly but can be obtained from the State Inpatient Database upon signing a data use agreement with the Agency for Healthcare Research and Quality. The R code for this study can be found in the GitHub repository: https://github.com/Weinbergerlab/RSVhospitalizations_USA/blob/main/RSV_burden.Rmd